Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or m
| Condition(s) | Type 1 Diabetes Mellitus |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or may be forgotten. With continuous glucose monitors (CGMs), PwT1D may be alerted to this missed insulin dose by a CGM alert, including rapidly rising glucose (change \>2.5mmol/L/15min) or hyperglycemia (\>10.0 mmol/L), and deliver a mistimed (post-prandial) dose in response to CGM alert. This study was designed to determine the effect of combining a post-prandial/mistimed insulin dose with 15 minutes of brisk walking. It is expected that walking will help to minimize or prevent |
| Who can participate | Inclusion Criteria: * Adults aged 18-24 years * Type 1 diabetes diagnostic for at least two years * Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9% * Use a Dexcom G7 CGM in routine care Exclusion Criteria: * Changes in insulin management strategy within the past 2 months * Diagnosis of gastroparesis * Having a condition that could render exercise harmful * Intolerance to gluten and lactose * Having significant renal disease (e.g., eGRF \< 30 ml/min) * Inability to provide informed consent due to cognitive deficit * Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been s |
| Ages | 18 Years to 24 Years |
| Sex | All |
| Lead sponsor | Jane Yardley |
| Locations | Montreal, Quebec, Canada |
| Start date | 2025-03-17 |
| NCT ID | NCT06686329 |
| Official listing | https://clinicaltrials.gov/study/NCT06686329 |